motexafin gadolinium
Diagnostic / imaging agent targets TXNRD1 via inhibition
Trials 32 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00717587 Background | Jun 2008 → Jul 2010 | kidney cancer | Abramson Cancer Center at Penn Medicine | Unknown | No outcome recorded |
| Phase 2 | NCT00514397 Background | Jan 2008 → ? | central nervous system neoplasm | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01082224 Background | Dec 2010 → Dec 2023 | liver cancer | American College of Radiology Imaging Network | Unknown | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Motexafin gadolinium | “Two hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed.” PMID 17401015 ↗ Apr 200734 |
| Known as | API-GP3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | FP-GP1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | GADOLINIUM TEXAPHYRIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | GD TEXAPHYRIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | GD-TEX | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | MGd | “Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)” NCT00076401 ↗4“Motexafin gadolinium (MGd) is a putative radiation enhancer initially evaluated in patients with brain metastases.” PMID 17560737 ↗ Jun 2007 “Phase I Trial of Motexafin Gadolinium (MGd) and Docetaxel Chemotherapy in the Treatment of Advanced Solid Tumors” NCT00120939 ↗ “Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer” NCT00129844 ↗ “MGd 10 mg/kg infused over approximately 30 to 60 minutes” NCT00373204 ↗ |
| Known as | MGd, Xcytrin (motexafin gadolinium) Injection, | “MGd, Xcytrin® (motexafin gadolinium) Injection,” NCT00089284 ↗ |
| Known as | Motexafin gadolinium anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | Motexafin gadolinium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544910 ↗ |
| Known as | NSC 695238 | “Gadolinium Texaphyrin (NSC 695238)” NCT00003798 ↗ |
| Known as | PCI-0120 | “OUTLINE: This is a multicenter, dose-escalation study of motexafin gadolinium (PCI-0120).” NCT00032097 ↗1“motexafin gadolinium (PCI-0120)” NCT00003411 ↗ |
| Known as | Xcytrin | “Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain...” NCT00054795 ↗3“Xcytrin® (motexafin gadolinium)” NCT00373204 ↗ “Xcytrin® (motexafin gadolinium)” NCT00365183 ↗ “Xcytrin” NCT01082224 ↗ |
| Action | Inhibit | “Thioredoxin reductase 1 inhibitor” CHEMBL3544910 ↗ |
| Modality | Diagnostic / imaging agent | “gadolinium texaphyrin as a tumor retained contrast agent” NCT00003410 ↗ |
| Route | Intravenous | “motexafin gadolinium IV over 10-15 minutes” NCT00003409 ↗ |
| Target | TXNRD1 | “Thioredoxin reductase 1 inhibitor” CHEMBL3544910 ↗ |